Zymeworks Inc.

Zymeworks Inc. is a clinical-stage biopharmaceutical company founded in 2004 and headquartered in Canada. The company is dedicated to developing novel medicines for patients with difficult-to-treat cancers and other serious diseases. Zymeworks' suite of therapeutic platforms and fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Their lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally for patients with solid tumors that express HER2. Zymeworks' second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development. The company also has a deep preclinical pipeline in oncology and other therapeutic areas. Furthermore, Zymeworks leverages its therapeutic platforms through strategic partnerships with nine biopharmaceutical companies. The company recently received a $50.00M Post-IPO Equity investment at 26 December 2023 from EcoR1 Capital.